· 2 min read
Defibrotide Found to Fight Blood Clots Beyond Its Known Mechanism
By Kristense at Havdis AI Science Team, approved by Andreas Lyhammer
· 2 min read
By Kristense at Havdis AI Science Team, approved by Andreas Lyhammer

Based on the PubMed abstract — the full text of this paper was not freely available.
Tettamanti and colleagues, writing in Life Sciences in 1992, looked into why defibrotide, a polydeoxyribonucleotide sodium salt used for its anti-clotting properties, works as well as it does. Until then, its effect was credited mainly to boosting tissue plasminogen activator, an enzyme that breaks down clots, while lowering a protein that blocks that enzyme.
The researchers tested defibrotide in mice with induced lung blood clots, a model in which reactive oxygen molecules known as free radicals play a central role. Defibrotide reduced clotting whether given into a vein or by mouth. In lab experiments with isolated cells, it also neutralized hydrogen peroxide (though not another reactive molecule, superoxide), reduced the release of a damaging enzyme from white blood cells called neutrophils, lowered light-emitting chemical signals produced by stimulated neutrophils, and cut the output of reactive oxygen from macrophages, another type of immune cell.
Based on these results, the authors proposed that defibrotide's anti-clotting action involves more than its known effect on clot-dissolving enzymes; it may also work by mopping up reactive oxygen species and calming the immune cells involved in clot formation. As an animal and cell-based study, it cannot show whether the same mechanisms apply in humans, nor does it describe defibrotide's chemical origin or dose purity.
Our reflection
This 1992 paper is a reminder that polydeoxyribonucleotides were studied for systemic, circulatory effects long before they entered skin and wound care. The mechanistic detail here, scavenging reactive oxygen species and modulating immune cell activity, reflects the kind of foundational pharmacology that later informed how PDRN's broader biological actions came to be understood. At Havdis, we view such early work as part of the scientific lineage that today's regenerative PDRN research builds upon, even though this study itself has no direct bearing on topical or aesthetic use.
Source
Tettamanti R, Bianchi G, Vitte PA, Kato G, Porta R, Thiemermann C et al. (1992). Life sciences.
Read the paper on PubMedDOI: 10.1016/0024-3205(92)90565-7
This article is written by Havdis's AI Science Team to explain published research. It is not medical advice, and nothing here is a claim about any Havdis product.
Related
A 1993 European Journal of Pharmacology study on how defibrotide, a polydeoxyribonucleotide, binds adenosine A1 and A2 receptors in lab experiments.
Read more →1992 Thrombosis Research study: defibrotide limited calcium overload and arrhythmia in low-flow perfused rabbit hearts via prostaglandin signaling.
Read more →1991 Angiology study: defibrotide limited calcium-driven neutrophil activation in lab tests, offering an early mechanistic clue for this PDRN-class drug.
Read more →